Author:
Greenberg William M.,Citrome Leslie
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference81 articles.
1. Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother. 2009;10:1917–28.
2. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–62.
3. Citrome L, Eramo A, Francois C, Duffy R, Legacy SN, Offord SJ, et al. Lack of tolerable treatment options for patients with schizophrenia. Neuropsychiatr Dis Treat. 2015;11:3095–104.
4. Citrome L, Johnston S, Nadkarni A, Sheehan JJ, Kamat SA, Kalsekar I. Prevalence of pre-existing risk factors for adverse events associated with atypical antipsychotics among commercially insured and Medicaid insured patients newly initiating atypical antipsychotics. Curr Drug Saf. 2014;9:227–35.
5. Food and Drug Administration. Drug approval package. Latuda (lurasidone hydrochloride) tablets. Sunovion Pharmaceuticals, Inc. clinical review; pharmacology review(s); clinical pharmacology biopharmaceutics review(s). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200603Orig1s000PharmR.pdf . Accessed 12 Jun 2016.
Cited by
49 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献